Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $477.37 0.00 (0.00%) 5:30 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $477.37 0.00 (0.00%) 5:30 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals
5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.
Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.
AstraZeneca (AZN) Q3 Earnings Top, Upgrades '19 Sales View
by Zacks Equity Research
AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.
Factors Setting the Tone for Celgene (CELG) Q3 Earnings
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q3 results.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week include acquisition news, and regulatory and pipeline updates.
The Zacks Analyst Blog Highlights: Chipotle Mexican Grill, Vertex Pharmaceuticals, American Electric Power Company, Verizon Communications and V.F.
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chipotle Mexican Grill, Vertex Pharmaceuticals, American Electric Power Company, Verizon Communications and V.F.
What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?
by Zacks Equity Research
Growth in Rapid Assays and Veterinary Software revenues is expected to get reflected in IDEXX's (IDXX) third-quarter results.
Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings?
by Zacks Equity Research
Persistent de-emphasizing of tobacco is hurting growth, which should get reflected in the upcoming quarterly results of Walgreens Boots Alliance (WBA).
Alexion Gets FDA Approval for Label Expansion of Ultomiris
by Zacks Equity Research
Alexion (ALXN) obtains FDA approval for the label expansion of Ultomiris for the treatment of ultra-rare disease, aHUS.
5 Large-Cap Stocks Set to Beat Earnings Estimates This Month
by Nalak Das
Third-quarter 2019 earnings results so far are not as disappointing as expected initially. However, the forecast of overall earnings dip in the third quarter is still looming large.
What's in Store for Align Technology's (ALGN) Q3 Earnings?
by Zacks Equity Research
We are optimistic that Align Technology's (ALGN) Invisalign product portfolio has shown continued strength in the third quarter.
Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
The Zacks Analyst Blog Highlights: Southern Company, Applied Materials, Vertex Pharmaceuticals, NVIDIA and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Southern Company, Applied Materials, Vertex Pharmaceuticals, NVIDIA and Edwards Lifesciences
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics Enters New License Agreement, Shares Up
by Zacks Equity Research
CRISPR Therapeutics (CRSP) looks to strengthen its CAR-T therapy programs through its agreement with KSQ Therapeutics.
Top Research Reports for Southern, Applied Materials & Vertex
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Southern Company (SO), Applied Materials (AMAT) and Vertex Pharmaceuticals (VRTX).
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.
Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Vertex Enters Into Collaboration With Privately-Held Ribometrix
by Zacks Equity Research
Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?